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INTRODUCTION
The concept that the hypothalamus controls anterior pituitary function via the
production of neurohormonal releasing and inhibitory factors (RFs and IFs, re-
spectively) is well documented (1).
There is a growing body of evidence relating endocrine disorders to hypothala-
mic dysfunction that has resulted in a wide variety of endocrine and metabolic
imbalances (2, 3). In an effort to explain the pathophysiologic expression of the
bizarre clinical entity known as lipoatrophic diabetes (LD), we have attempted
to correlate our laboratory findings with the current knowledge regarding hypo-
thalamic-hypophyseal-target organ interactions.
Generalized or total lipoatrophic diabetes, relatively rare, has long been thought
to be genetically determined. The onset of the disease is frequently heralded by
fever. This disease is characterized by a loss of subcutaneous and other body fat,
skeletal muscle overgrowth, bone overgrowth with advance maturation, hepato-
megaly, splenomegaly, genital enlargement, hyperpigmentation of the skin with
acanthosis nigricans, hyperlipemia, and insulin-resistant hyperglycemia.
Our more recent clinical data gives substantive chemical evidence that hypothal-
amic dysfunction may exist in patients with LD (4, 5) substantiating the early
speculations of Seip in 1959 (6). Our patients had apparently normal circulating
levels of pituitary hormones in the face of clinical evidence suggesting obvious ex-
cessive hormonal stimulation. Plasma from one of these patients who had been
hypophysectomized in an effort to alleviate the metabolic and physical distortions
of the disease, revealed comparable levels of releasing factors [corticotropin-releas-
ing factor (CRF), follicle-stimulating hormone releasing factor (FRF), and
melanocyte-stimulating hormone releasing factor (MRF)] both pre- and postopera-
tively. These data indicated that the pituitary in situ had no effect on the progres-
sion or amelioration of the disease and implicated hypothalamic involvement.
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Subsequent study of five patients with generalized lipodystrophy has established
the presence in the plasma, of detectable releasing-factor activity as a consistent
finding in association with the other symptoms of this disease (4, 5).
The demonstration of releasing-factor activity in the plasma of these patients
was unexpected in view of the demonstrated absence of such activity in the intact
human (7). Animal studies have demonstrated that detectable levels of releasing
factor (FRF and CRF) are present in the peripheral plasma of hypophysectomized
preparations (8, 9). Corbin et al. (7) corroborated and extended these findings
by demonstrating the presence of levels of follicle-stimulating hormone releasing
factor (FRF) and luteinizing hormone releasing factor (LRF) activities in the
plasma of a hypophysectomized human. Studies on the "internal" feedback phe-
nomenon [the ability of an anterior pituitary hormone to effect, by itself, and in
the absence of peripheral target organ hormone intervention, its respective hypo-
thalamic releasing factor (RF) and inhibiting factor (IF)] in animals (8, 10),
prompted us to speculate whether such a mechanism existed in humans. The
lipodystrophic patients appeared as functionally hypophysectomized and we admin-
istered corticotropin (ACTH) in an effort to simulate the internal feedback (5,
11). A significant reduction in plasma CRF activity was observed in three out
of four LD patients. The normal control showed no detectable level of CRF before
or after ACTH. It remained an enigma that exogenous hormones could eliminate
the RF in most LD patients but that the endogenous levels of corticotropin present
were ineffective.
PATHOPHYSIOLOGY
1. Feedback
Originally it was thought that the muscle and bone overgrowth and the hyperpig-
mentation were due to hypersecretion of growth hormone and melanocyte-stimulat-
ing hormone (MSH), respectively. Since the releasing factors have been implicated
in the biosynthesis of pituitary hormones (12-14), it was possible that structural
variants of pituitary hormones were produced, resulting in the clinical pathophysi-
ology observed. These hormonal variants themselves may not possess any inhibi-
tory feedback effects. However, the persistence of this disease entity in the hy-
pophysectomized patient precluded hypophyseal involvement (15). If the syn-
drome had been ameliorated by the hypophysectomy, it would have been tempting
to speculate further that the refractoriness of the hypothalamus to regulation by
the hypophyseal-target organ axis, led to releasing factor hypersecretion. On the
other hand, one can speculate that the RFs may be secondary to a generalized
hypothalamic derangement with the actual metabolic defect residing at the receptor
site levels of the various tissues (fat, muscle, bone, skin) where the disease is
manifested.
2. Hypothalamic Biogenic Amines
There is a growing body of evidence that implicates multiple monoaminergic
neuronal systems in the control of the secretion of most, if not all, of the hormones
secreted by the pituitary gland. Modification of the synthesis, release, or metabo-
lism of brain catecholamines has been shown to interfere with secretion of anterior
pituitary hormones (16-18).
Norepinephrine, dopamine, and serotonin appear to be transmitters at synaptic
junctions in the basal medial hypothalamus regulating the secretion of the hypo-
3156UPTON AND CORBIN
physiotropic hormones (RFs and IFs) which in turn regulate the secretion of the
pituitary hormones (19). Our discussion will be confined to norepinephrine and
dopamine because of the scanty evidence concerning the role of serotonin and its
relative importance to this control system.
Relatively large amounts of norepinephrine and dopamine are stored in the
median eminence as demonstrated by chemical assays (20, 21). Morphological
studies have shown that discrete populations of neurons which contain these mono-
amines end in the hypothalamus (22). The generalized scheme describing the inter-
connections between catecholamine neurons and RF/IF neurons with the hypo-
physiotropic area is presented in Fig. 1. L-dopa in man (23-26) can stimulate the
release of CRF, prolactin-inhibiting factor, FRF, and LRF. Since L-dopa is decar-
boxylated to dopamine and thence to norepinephrine by the action of dopamine-,8-
hydroxylase, it is possible that either dopamine or norepinephrine or both may
subserve the hypothalamic RF/IF mechanism.
Fluctuations of norepinephrine content occurs in certain states of altered en-
docrine balance, e.g., turnover of norepinephrine increases after adrenalectomy but
decreases after hypophysectomy (27, 28). Data supplied mainly by Ganong (29)
has supported the existence of a central noradrenergic system that inhibits ACTH
secretion. The inhibitory role of norepinephrine neurons is strengthened by experi-
mental results indicating that rises in tonic corticosterone secretion increase after
lesions of ascending norepinephrine pathways (30).
Further results obtained by systemic treatment with such drugs as dopa, am-
phetamine, chlorpromazine, and reserpine clearly suggest an inhibitory role for the
norepinephrine system (31, 32).
Many studies support the conclusion that releasing and inhibiting factors are
present in the basal medial hypothalamus (hypophysiotropic area), that they are
HYPOPHYSIOTROPIC
AREA HYPOTHALAMUS
| CA NEURON
P RF/IF NEURON ANTERIOR PITUITARY HORMONES
FIG. 1. Generalized scheme describing interconnections between catecholamine-producing
and RF/IF-producing neurons within the hypothalamus. (MAM = mamillary body; OC = op-
tic chiasma; AL = anterior hypophyseal lobe; PL = posterior hypophyseal lobe; ME = median
eminence; RF/IF = releasing factor/inhibitory factor; CA = catecholamine)
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present in portal blood and that dopamine induces discharge of these substances
from neurosecretory elements of the hypothalamus (33).
In view of these data suggesting inhibition by norepinephrine and stimulation
by dopamine, it is tempting to speculate that in the LD patient, lowered norepi-
nephrine secretion and dopamine excess resulted in constant elevated secretion of
releasing factors.
3. Metabolic Considerations
One of the more consistent features of LD is the presence of insulin resistance
and is remarkable because the resultant hyperglycemia rarely leads to ketosis. It
is important to note in this context that the hypophysiotropic area exerts an impor-
tant regulatory effect on glucose homeostasis and contains within its functional
boundaries the hypothalamic loci involved in the control of insulin release (34)
and lipid metabolism (35). Largely from the work of Frohman (36) it has been
demonstrated that the hypothalamic control is dual in nature, involving both the
sympathetic and parasympathetic components of the autonomic nervous system.
The ventromedial nucleus and the ventrolateral hypothalamus represent the origin
of circuits that directly innervate the liver via the sympathetic and parasympathetic
outflow systems, respectively.
It is also possible that a defective adenyl cyclase system is present in the LD
such as has been postulated by Cerasi and Luft for diabetes mellitus (37). Reduced
tissue sensitivity to insulin or an increased sensitivity to or excess production of
catecholamines results in the metabolic derangements. A defective adenyl cyclase
system could explain the lack of response of the pituitary to the excessive produc-
tion of RF. Again, this insensitivity to endogenous RF would implicate extrapitu-
itary effects of the RFs.
Whatever the mechanisms involved there can be little doubt that the work of
Frohman lays the foundation for a direct correlation between the presence of the
hypothalamic disorder and the presenting diabetic symptoms.
THERAPEUTIC IMPLICATIONS
Within this theoretical framework, we attempted manipulation of the hypo-
thalamic hypophysiotropic mechanism by pharmacological blockade of dopamine.
It would follow that drugs which increase the "tone" of the adrenergic systems
(either through increased catecholamine secretion or direct stimulation of adrener-
gic receptors) may lead to increased output of hypophysiotropic factors; con-
versely, agents which dampen the adrenergic system may lead to attenuation or
inhibition of the RF mechanism.
Table 1 is a compilation of various classes of pharmacological agents which can
affect the adrenergic (dopamine and norepinephrine) mechanism, through biosyn-
thetic pathways (preloading with precursors or inhibition of transforming enzymes)
or through direct effects on nerve terminal receptors (receptor inhibition and stimu-
lation, displacement and/or depletion of native neurotransmitters or direct destruc-
tion of the terminals themselves).
The work of Sherman and Kolodny (38) and Kolodny et al. (39), has supported
the hypothesis that chronic hypersecretion of growth hormone in certain cases of
acromegaly and gigantism is nonautonomous and is due to hypothalamic dysfunc-
tion. They demonstrated that drugs interfering with catecholamine output, such
as chlorpromazine, were effective in markedly lowering growth hormone concentra-
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TABLE I
IIAJ(otI EFFECTS OF D)RUGS ON BRIuN 1)OPAMINE (I)A) AND NoImPINEPHRINE (NE)
l'iinspi(le (dipl.e .lbtYlpipeidies) FItllsp)irilelles >l)llylltl)lllllt9
Apoiinorphine
ET 495
ca-Methlyl(lopa hlydraz(inle
(s-Met}hvylty OSllle
(s-AIethyld(opa (Ald)mnet)
D)isulfiraIm1
I)DC (dietlividithliocal rba imate)
FLA-63
Plhenitolaimiine
Plropr ainolol, Pr oinethalol, Pin(dolol
I )OPS ((dillhy(lloxyphellA lserinle)
lleseripine
l'argyliie, TriaInylcypr omiine, Nialamide
1 inipramine, Amitriptylinie (tIricyclic aIlti-
dleplressives)
i,-Dopa
(;-()I 1)opamine
Glua netluidine
Spiropenidol )
Italoperidol 2 (hutyroplheltolIes)
AMethylperidol)
Fluphenazine
f(phenot} hiazines) 1'eiplieiiaziiie
('lopenthixol | (tioxantienes)
Fluipenitliixol (
(lothiapine (dibenzazepine)
I'PlenloxY )en ainnllille
'I'mlioli izilleo C}slo p ot alixille,
P'ipamlperone, Clilorpi omnaziiieJ
Effect
Selective lblocker of D)A receptors
Short-acting D)A receptor-stimulating agenit
Blocks conversion of levodopa to dopamine onily witliini
peripheral tissues
Inhibits tvrosine hy(Iroxylase atin( lea(1s to eventual de-
crease of (dopamine aIl(1 NE
Produces a-metlix D)A and(i a-mlethyl NE whliich act as
false transmitters and (lispllace DA anid NEI
Inhibit (lopaminle-13-llyroxylase whichplreellts trans-
foI-mationi of DA to NE
a-A(lrenergic l)locker
O-AdIenergic blocker
Iicreases NE synthesis (I)OPS is precursor for NE)
Depletion of DA aIl(l N1E,
MIAO inhibitors-raise DA and(i NE
Inhibit, uptake of DA andl NE
Incr-ease I)A and(i NE'
I)epletes amid (lestroys NE termninlals
D)epletes NE terminals (peripheral tissue)
Block )A receptors, simall effect oni NE receptors
Block 1)A receptors, siall effect onI NE' receptors
Block D)A receptors, small effect on NE receptors
Blocks both DA anI(d NE receptors
Blocks NE receptors
Weak and(i equal blockers of 1)A. and(l NE receptors
tions and eliminating the headaches and visual disturbances of an acromegalic
patient.
Since chlorpromazine was presumably acting through its central nervous system
antiadrenergic effect, this drug (100 mg/day) was administered to our lipo-
dystrophic patients and control subjects over 21 days. The initial response to the
drug was a reduction in the levels of releasing factors followed by a subsequent
return of both CRF and FRF to levels seen before drug administration. The normal
patients initially had no detectable level of RF, although after 21 days of therapy,
CRF and not FRF levels were detectable. It was, therefore, impossible for us to
318HYPOTHALAMIC DYSFUNCTION AND DIABETES
decide whether the CRF levels shown in the LD patients after 3 weeks were due
to the disease state or to the effects of the drug; very likely both factors contributed.
The picture with FRF appears clearer. The increasing level of FRF activity towards
preexisting values is interpreted as a reflection of the hypothalamic dysfunction
overriding the apparent drug effect. On the basis of our findings, chlorpromazine
did not appear to be the drug of choice.
Hypothesis
Figure 2 depicts the normal conversion pathway of tyrosine to dopamine and
norepinephrine in the brain and its effect on the neurosecretory cell at the level
of the hypothalamus. On the basis of our data showing a constant release of hy-
pophysiotropic hormones in the lipoatrophic diabetes syndrome, the problem is
presumed to be hypothalamic in origin. There may exist a genetically transferred
inborn error in metabolism that inhibits the normal metabolism of tyrosine in the
brain. This defect may possibly exist as a lack of dopamine-,8-hydroxylase, the
enzyme necessary to convert dopamine to norepinephrine. When insufficient
amounts of norepinephrine are present, the normal inhibition of the releasing factors
is removed and constant uncontrolled stimulation of the releasing factors by exces-
sive amounts of dopamine results.
It is noteworthy that the lipoatrophic diabetes syndrome persisted in the single
patient who had been hypophysectomized. Moreover, the continued presence of
pigmentation in this patient would indicate that hypophyseal MSH was not in-
volved. It is tempting to speculate that excess dopa was present and was eventually
metabolized to dopa-melanin in the skin (40). An interesting but speculative cor-
relation arises from this suggestion: the activity of tyrosinase, the enzyme which
converts tyrosine to L-dopa, and also L-dopa to dopaquinone which is eventually
metabolized to dopa-melanin, is temperature dependent. Increased temperature ac-
celerates the tyrosinase reaction and might account for the excess dopa and its
subsequent metabolism to dopa-melanin, resulting in the increased pigmentation
FLA-63
a-methyl-m-tyrosine DDC
a-methyl-p-tyrosine a-methyldopa Disulfiram DOPS
TYO tEyrosne1~DP Dopa eopamine i TY ROS~eI decarboxyOase DOPAMINE ydroxyasi ''[-ORPIEHRN hydroxylasel_D0PA decarboxylase DOPAMINEh eLase NOREPlNEPHRhNE
Phentolamine
11 BLOCK Chlorpromazine
l) STIMULATION
s"' RECEPTOR SITE
Pimozide RF/IF Neuron
ET 495
ME
Anterior Pituitary
FIG. 2. Schematic representation of the metabolism of tyrosine in the brain and the relation-
ship to hypophysiotropic hormones. Sites of action of various drugs are indicated at various
steps. (FLA-63 = bis (4-methyl-l-homopiperazinyl-thiocarbonyl) disulfide; ET 495 =
7-(2"-pyrimidyl-4-1 piperonyl-piperazine); DDC = diethyldithiocarbamate; DOPS = dihydroxy-
phenylserine; ME = median eminence; RF/IF = releasing factor/inhibitory factor)
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seen in the body folds and in skin chronically exposed to heat sources. As infants,
and recently, these patients have experienced bouts of abnormal hyperthermia,
which may have been harbingers and perpetrators of the eventual hypothalamic
dysfunction.
A further extension of the excess dopamine hypothesis may be based on the
recent findings of Weinshilboum and Axelrod (41) and Fuxe et al. (42), who
demonstrated that dopamine-,8-hydroxylase increases in the blood of rats after hy-
pophysectomy. Since hypophysectomy (as well as LD) leads to increased levels
of releasing factors in the peripheral circulation and since dopamine appears to
be the major neurotransmitter subserving the hypothalamic-hypophysiotropic hor-
mone mechanism, the rise in dopamine-,8-hydroxylase may represent a compensa-
tory response to the absence of all feedback input. It can only be conjectured at
this time that the increased dopamine-/a-hydroxylase may be an attempt to convert
excessive dopamine to norepinephrine, thus reducing the "drive" to the releasing
factor mechanism. However, one may argue against this concept, since the un-
treated lipoatrophic diabetes patient (whether hypophysectomized or not) pos-
sesses persistent blood RF activities and this fact necessitates that we postulate
a defect at the rate-limiting step (dopamine-,8-hydroxylase) in the conversion of
dopamine to norepinephrine.
The constant secretion of releasing factor is not affected by an internal feedback
control and the levels of circulating pituitary hormones appear normal. This ob-
servation might be explained by increased catabolism of the pituitary hormones,
although we have no data to support this assumption. The bizarre effects on lipid
metabolism may be due to the excessive release of lipid-mobilizing factor which
may also be controlled by hypothalamic neurons (43).
The pathological modification of brain catecholamines is expressed as RF hyper-
secretion as one component and certainly can affect other parameters, e.g., insulin
levels, lipid mobilization, glucose metabolism. Since the collective evidence under-
scores the important and unique role of dopamine in regulating the hypothala-
mic-endocrine axis, it would follow that selective inhibitors of this catecholamine
may be useful in the treatment of hypothalamically based diseases and hopefully
will ameliorate the symptoms of this bizarre, disfiguring, and inevitably fatal dis-
ease. Data derived from our recent animal and clinical LD studies, employing
Pimozide, a dopamine receptor blocker, tentatively support this hypothesis.
SUMMARY
The hypothesis is proposed that:
1. Lipoatrophic diabetes appears to possess a hypothalamic component, perhaps
involving a genetically transferred defect in the enzyme, dopamine-,p-hydroxylase.
2. Absence of normal inhibition by norepinephrine and unchecked stimulation
by excess dopamine may be the cause of autonomous RF hypersecretion.
3. Internal feedback control appears nonexistent.
4. Hyperpigmentation cannot be due to MSH, since skin darkening persists after
hypophysectomy. Dopa-melanin may account for the hyperpigmentation.
5. The persistence of the disease in the absence of the pituitary implicates an
extrapituitary effect by releasing factors. Increased blood RF's may be secondary
to a generalized hypothalamic derangement with the actual metabolic defect resid-
ing at the receptor site of the various tissues (fat, muscle, bone, skin) where the
disease is manifested.
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6. Dopamine receptor blockers that block the effect of this neurotransmitter in
the hypothalamus at the level of the neurosecretory cell, inhibitors of dopamine
synthesis or stimulators of norepinephrine synthesis, should ameliorate the symp-
toms of this bizarre and disfiguring disease.
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